|

D3S-001 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Pipeline

Phase 1/2: 2

Top Sponsors

  • D3 Bio (Wuxi) Co., Ltd2

Indications

  • Cancer2
  • Advanced Solid Tumors With MAPK Pathway Mutations1
  • KRAS P.G12C1

Orange, California1 trial

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

D3 Bio Investigative Site 0402

Phase 1/2

Detroit, Michigan1 trial

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

D3 Bio Investigative Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.